A liver protection function experimental protocol provides a systematic, standards-aligned framework for evaluating the hepatoprotective efficacy of health foods, botanical extracts, and functional ingredients using validated in vivo and in vitro models. The protocol integrates chemically induced liver injury models, serum biomarker analysis, hepatic antioxidant assays, and histopathological examination to generate scientifically defensible evidence for functional claim substantiation and regulatory submission. Studies are conducted by accredited third-party laboratories in accordance with internationally recognized guidelines such as OECD test guidelines and GB national standards to ensure data reliability and regulatory acceptance.
Technical Overview
The liver protection function experimental protocol is a structured testing plan designed to verify whether a test substance can prevent or attenuate chemical-, alcohol-, or diet-induced liver injury. The evaluation is built on three complementary evidence pillars: reduction of hepatocellular damage measured through serum enzymology, improvement of hepatic antioxidant capacity, and histopathological confirmation of tissue protection. Together, these endpoints establish a weight-of-evidence assessment of hepatoprotective function suitable for product development and regulatory documentation.
Typical evaluation dimensions include:
- Serum liver function biomarkers, primarily alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and total bilirubin (TBIL)
- Hepatic oxidative stress indicators, including superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GSH-Px), catalase (CAT), and malondialdehyde (MDA)
- Liver organ index and histopathological scoring of hematoxylin-eosin (HE) stained sections
- Inflammatory and lipid metabolism markers such as TNF-alpha, IL-6, and hepatic triglyceride content, where applicable
- In vitro cytoprotective screening using human or rodent hepatocyte lines
The protocol is typically executed under Good Laboratory Practice (GLP) principles in facilities accredited to ISO/IEC 17025, with animal care programs aligned to internationally recognized welfare standards and the 3Rs principle (replacement, reduction, refinement).
Testing Samples
Health Foods and Dietary Supplements
Finished dosage forms intended for oral administration, including tablets, hard and soft capsules, oral liquids, granules, and powders. Both market-ready products and pilot-scale batches can be evaluated, provided the sample is representative of the intended commercial formulation.
Botanical Extracts and Functional Ingredients
Plant-derived active ingredients such as silymarin from milk thistle, lignans from Schisandra chinensis, isoflavones from Pueraria lobata, polysaccharides, and polyphenol-rich extracts. Samples should be accompanied by composition data, specification sheets, and recommended human daily intake for dose conversion.
Pharmaceutical and Preclinical Candidates
New chemical entities, natural product candidates, and traditional medicine formulations under preclinical development, where hepatoprotective pharmacodynamic profiling supports investigational submissions.
Functional Foods, Beverages, and Novel Food Ingredients
Functional beverages, fermented products, edible fungi preparations, and novel ingredients requiring scientific substantiation of liver-related health benefits for marketing or notification purposes.
Testing Items
The core testing panel covers the following item groups:
- Serum enzymology: ALT, AST, AST/ALT ratio, ALP, GGT for the assessment of hepatocellular and cholestatic injury
- Metabolism and secretion function: total bilirubin, direct bilirubin, total protein, albumin, and hepatic triglyceride and total cholesterol levels
- Antioxidant capacity: SOD, GSH, GSH-Px, CAT activity, and MDA content in liver homogenate
- Inflammation markers: TNF-alpha, IL-1 beta, IL-6 quantified by ELISA where the study design requires mechanistic support
- Histopathology: liver organ index, HE staining of liver sections, steatosis, necrosis, inflammatory infiltration, and fibrosis scoring performed by blinded pathologists
- In vitro endpoints: cell viability (MTT or CCK-8), LDH leakage, intracellular ROS levels, and apoptosis analysis (Annexin V/PI flow cytometry)
- Supporting safety items: body weight, food and water intake, and general behavioral observation throughout the dosing period
Testing Methods
In Vivo Hepatoprotective Models
Multiple chemically and diet-induced liver injury models are available, selected according to the intended claim of the product:
- Carbon tetrachloride (CCl4)-induced acute or chronic liver injury: the most widely used screening model for general hepatoprotection, evaluated at 16 to 24 hours after challenge
- Alcohol-induced liver injury: repeated ethanol administration modeling oxidative damage and fatty degeneration relevant to alcohol-associated claims
- D-galactosamine (D-GalN)-induced injury: a model mimicking diffuse inflammatory hepatic damage
- Acetaminophen (APAP)-induced injury: an overdose-associated necrosis model for mechanism-oriented evaluation
- High-fat diet-induced non-alcoholic fatty liver model: suited to products targeting lipid metabolism and steatosis
Study Design and Grouping
A standard design uses SPF-grade ICR/KM mice or SD/Wistar rats randomized by body weight into a blank control group, a model control group, a positive control group (typically silymarin or bifendate), and three dose groups of the test substance. Doses are generally set at multiples of the recommended human daily intake, converted by body surface area, and administered by oral gavage for 30 to 35 consecutive days. Sample size is determined by power analysis in line with ethical reduction principles.
Biochemical and Histopathological Analysis
Serum ALT and AST are measured on automated clinical chemistry analyzers using internationally standardized kinetic methods. Antioxidant and lipid indicators in liver homogenate are quantified with validated colorimetric assay kits. Liver tissues are fixed, paraffin-embedded, HE-stained, and scored in a blinded manner, with pathological grading criteria documented in the raw data.
In Vitro Screening Models
Cell-level assays use HepG2, HL-7702/L02 human normal hepatocyte lines, or primary hepatocytes challenged with CCl4, ethanol, hydrogen peroxide, or APAP. Cytoprotective activity is demonstrated by improved cell viability, reduced LDH release, and suppressed ROS accumulation, providing mechanistic support and early-stage screening before animal studies.
Quality Assurance and Standards Compliance
Studies follow OECD Principles of Good Laboratory Practice, relevant OECD test guidelines for repeated-dose toxicity, and GB national food safety standards for toxicological testing procedures. Test facility competence is verified through ISO/IEC 17025 accreditation, and animal programs are maintained in accordance with recognized welfare accreditation schemes with institutional ethics committee approval.
Applications
The liver protection function experimental protocol supports a wide range of commercial and scientific objectives:
- Functional claim substantiation dossiers for health food registration and market notification in regulated jurisdictions
- Scientific evidence packages accompanying product labeling, marketing materials, and clinical nutrition communications
- Formulation screening and dose optimization during research and development
- Comparative benchmarking of new formulations against positive control reference substances
- Ingredient supplier verification and batch-to-batch functional consistency assessment
- Peer-reviewed publication and mechanistic research on hepatoprotective mechanisms
FAQ
What sample quantity and documentation should be submitted?
Applicants typically submit a quantity sufficient for all dose groups across the full dosing period plus retention samples, along with the composition specification, recommended human daily intake, physical properties, and any solubility or stability information that guides vehicle selection.
How is the appropriate liver injury model selected?
Model selection follows the product positioning: CCl4 models serve general hepatoprotection claims, alcohol models support alcohol-related claims, and high-fat diet models suit lipid metabolism and fatty liver applications. A technical consultation before study initiation aligns the model with the intended claim.
What is the typical project timeline?
A standard in vivo study, including animal acclimatization, a 30 to 35 day dosing period, post-challenge observation, biochemical and histopathological analysis, and report issuance, generally requires six to ten weeks depending on model complexity and sample queue.
What criteria define a positive hepatoprotective result?
A positive outcome is declared when serum ALT and AST levels are significantly reduced compared with the model control group, accompanied by improvement in antioxidant indicators and histopathological evidence, ideally showing a dose-response relationship across tested doses.
Are animal welfare and ethical requirements observed?
Yes. All procedures are reviewed and approved by the institutional animal care and ethics committee, performed by trained personnel, and designed to minimize animal use and distress in line with the 3Rs principle and applicable national regulations.
Can in vitro results alone substantiate a liver protection claim?
In vitro data provide valuable mechanistic and screening support but are generally combined with in vivo results to form a complete evidence package. Regulatory submissions typically require animal efficacy data, while in vitro assays strengthen the mechanistic narrative of the dossier.